

RECEIVED  
CENTRAL FAX CENTER

+6504738654

T-351 P.001

F-750

AUG 17 2004

OFFICIAL

PTO/SB/21 (04-04)

Approved for use through 07/31/2008. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


<b>TRANSMITTAL FORM</b> (to be used for all correspondence after initial filing)	Application Number	09/593,316
	Filing Date	June 13, 2000
	First Named Inventor	John Clark, et al.
	Art Unit	1632
	Examiner Name	Qian Janice Li
	Attorney Docket Number	730/002
Total Number of Pages in This Submission		86

LAST PAGE MARKED


## ENCLOSURES (Check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request (in duplicate) <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Supplemental Information Disclosure Statement (2 pages) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks Form PTO-1449 (1 page) with copies of 14 references		

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	J. Michael Schiff, Registration No. 40,253
Signature	
Date	August 13/04

## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.		
Typed or printed name	Karen Zislen	
Signature		Date August 17, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/17 (10-03)

Approved for use through 07/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 180

## Complete if Known

Application Number	09/593,316
Filing Date	June 13, 2000
First Named Inventor	John Clark, et al.
Examiner Name	Qian Janice Li
Art Unit	1632
Attorney Docket No.	730/002

## METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None☒ Deposit Account:Deposit Account Number  
Deposit Account Name

07-1139

Geron Corporation

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments☒ Charge any additional fee(s) or any underpayment of fee(s)☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

## FEE CALCULATION

## 1. BASIC FILING FEE

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1001 770	2001 385	Utility filing fee	
1002 340	2002 170	Design filing fee	
1003 530	2003 265	Plant filing fee	
1004 770	2004 385	Reissue filing fee	
1005 180	2006 80	Provisional filing fee	
SUBTOTAL (1)			(\$ 0

## 2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Extra Claims	Fee from below	Fee Paid
Independent Claims	-20** =	X	
Multiple Dependent	-3*** =	X	

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1202 18	2202 9	Claims in excess of 20	
1201 88	2201 43	Independent claims in excess of 3	
1203 290	2203 145	Multiple dependent claim, if not paid	
1204 88	2204 43	** Reissue independent claims over original patent	
1205 18	2205 9	** Reissue claims in excess of 20 and over original patent	
SUBTOTAL (2)			(\$ 0

\*\*or number previously paid, if greater; For Reissues, see above

## FEE CALCULATION (continued)

## 3. ADDITIONAL FEES

Large Entity Small Entity

Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid
1051 130	2051 65	Surcharge - late filing fee or oath	
1052 50	2052 25	Surcharge - late provisional filing fee or cover sheet	
1053 130	1053 130	Non-English specification	
1812 2,520	1812 2,520	For filing a request for ex parte reexamination	
1804 920*	1804 920*	Requesting publication of SIR prior to Examiner action	
1805 1,840*	1805 1,840*	Requesting publication of SIR after Examiner action	
1251 110	2251 55	Extension for reply within first month	
1252 420	2252 210	Extension for reply within second month	
1253 950	2253 475	Extension for reply within third month	
1254 1,480	2254 740	Extension for reply within fourth month	
1255 2,010	2255 1,005	Extension for reply within fifth month	
1401 330	2401 165	Notice of Appeal	
1402 330	2402 165	Filing a brief in support of an appeal	
1403 290	2403 145	Request for oral hearing	
1451 1,510	1451 1,510	Petition to institute a public use proceeding	
1452 110	2452 55	Petition to revive - unavoidable	
1453 1,330	2453 665	Petition to revive - unintentional	
1501 1,330	2501 665	Utility issue fee (or reissue)	
1502 480	2502 240	Design issue fee	
1503 640	2503 320	Plant issue fee	
1460 130	1460 130	Petitions to the Commissioner	
1807 50	1807 50	Processing fee under 37 CFR 1.17(q)	
1806 180	1806 180	Submission of Information Disclosure Stmt	180
8021 40	8021 40	Recording each patent assignment per property (times number of properties)	
1809 770	2809 385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810 770	2810 385	For each additional invention to be examined (37 CFR 1.129(b))	
1801 770	2801 385	Request for Continued Examination (RCE)	
1802 900	1802 900	Request for expedited examination of a design application	

Other fee (specify)

\*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$ 180

(Complete if applicable)

## SUBMITTED BY

Name (Print/Type)

J. Michael Schiff

Registration No.  
(Attorney/Agent)

40,253

Telephone

(650) 473-7715

Signature

Date

August 15/04

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-8199 and select option 2.

PTO/SB/17 (10-03)

Approved for use through 07/31/2008. OMB 0831-0032  
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE  
unless it displays a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**FEE TRANSMITTAL**  
**for FY 2004**

Effective 10/01/2003. Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 180

**Complete if Known**

Application Number	09/593,316
Filing Date	June 13, 2000
First Named Inventor	John Clark, et al.
Examiner Name	Qian Janice Li
Art Unit	1632
Attorney Docket No.	730/002

**METHOD OF PAYMENT (check all that apply)**☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None☒ Deposit Account:

Deposit Account Number	07-1139
Deposit Account Name	Geron Corporation

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments  
☒ Charge any additional fee(s) or any underpayment of fee(s)  
☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.
**FEE CALCULATION****1. BASIC FILING FEE**

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1001 770	2001 385	Utility filing fee	
1002 340	2002 170	Design filing fee	
1003 530	2003 265	Plant filing fee	
1004 770	2004 385	Reissue filing fee	
1005 160	2005 80	Provisional filing fee	
<b>SUBTOTAL (1)</b>			<b>(\$)</b> 0

**2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE**

Total Claims	Extra Claims	Fee from below	Fee Paid
Independent	-20** =	X	
Multiple Dependent	-3** =	X	

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1202 18	2202 9	Claims in excess of 20	
1201 88	2201 43	Independent claims in excess of 3	
1203 280	2203 145	Multiple dependent claim, if not paid	
1204 86	2204 43	** Release independent claims over original patent	
1205 18	2205 9	** Release claims in excess of 20 and over original patent	
<b>SUBTOTAL (2)</b>			<b>(\$)</b> 0

\*\*or number previously paid, if greater. For Reissues, see above

**FEE CALCULATION (continued)****3. ADDITIONAL FEES**

Large Entity Small Entity

Fee Code (\$)	Fee Code (\$)	Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid
1051 130	2051 66	1051 130	2051 66	Surcharge - late filing fee or oath	
1052 50	2052 25	1052 50	2052 25	Surcharge - late provisional filing fee or cover sheet	
1053 130	2053 130	1053 130	2053 130	Non-English specification	
1812 2,520	2812 2,520	1812 2,520	2812 2,520	For filing a request for <i>ex parte</i> reexamination	
1804 820*	2804 820*	1804 820*	2804 820*	Requesting publication of SIR prior to Examiner action	
1805 1,840*	2805 1,840*	1805 1,840*	2805 1,840*	Requesting publication of SIR after Examiner action	
1251 110	2251 55	1251 110	2251 55	Extension for reply within first month	
1252 420	2252 210	1252 420	2252 210	Extension for reply within second month	
1253 860	2253 475	1253 860	2253 475	Extension for reply within third month	
1254 1,480	2254 740	1254 1,480	2254 740	Extension for reply within fourth month	
1255 2,010	2255 1,005	1255 2,010	2255 1,005	Extension for reply within fifth month	
1401 930	2401 165	1401 930	2401 165	Notice of Appeal	
1402 330	2402 165	1402 330	2402 165	Filing a brief in support of an appeal	
1403 290	2403 145	1403 290	2403 145	Request for oral hearing	
1451 1,510	2451 1,510	1451 1,510	2451 1,510	Petition to institute a public use proceeding	
1452 110	2452 55	1452 110	2452 55	Petition to revive - unavoidable	
1453 1,330	2453 665	1453 1,330	2453 665	Petition to revive - unintentional	
1501 1,330	2501 665	1501 1,330	2501 665	Utility issue fee (or reissue)	
1502 480	2502 240	1502 480	2502 240	Design issue fee	
1503 640	2503 320	1503 640	2503 320	Plant issue fee	
1480 130	2480 130	1480 130	2480 130	Petitions to the Commissioner	
1807 50	2807 50	1807 50	2807 50	Processing fee under 37 CFR 1.17(q)	
1808 180	2808 180	1808 180	2808 180	Submission of Information Disclosure Stmt	
8021 40	2821 40	8021 40	2821 40	Recording each patent assignment per property (times number of properties)	
1809 770	2809 385	1809 770	2809 385	Filing a submission after final rejection (37 CFR 1.128(a))	
1810 770	2810 385	1810 770	2810 385	For each additional invention to be examined (37 CFR 1.128(b))	
1801 770	2801 385	1801 770	2801 385	Request for Continued Examination (RCE)	
1802 900	2802 900	1802 900	2802 900	Request for expedited examination of a design application	

Other fee (specify)

\*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$) 180

(Complete if applicable)

<b>SUBMITTED BY</b>		<b>Registration No.</b>	<b>40,253</b>	<b>Telephone</b>	<b>(650) 473-7715</b>
Name (Print/Type)		J. Michael Schiff		Date	
Signature		[Signature]		August 18/04	

**WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1460, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1460, Alexandria, VA 22313-1450.

RECEIVED  
CENTRAL FAX CENTER

+8504738654

T-351 P.004

F-750

AUG 17 2004

OFFICIAL

## CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence is being transmitted to the U.S. Patent & Trademark Office  
in accordance with 37 CFR § 1.6(d) on the date indicated.

Name

Date

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors: John Clark, *et al.*

Art Unit: 1632

Filing Date: June 13, 2000

Examiner: Qian Janice Li

Serial No: 09/593,316

Docket: 730/002

Title: ANIMAL TISSUE FOR  
XENOTRANSPLANTATIONSUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 CFR § 1.97(c)(2)Commissioner for Patents  
Alexandria VA 22313

Dear Sir,

The information listed in the accompanying form PTO-1449 and provided herewith may be material to examination of this application and is submitted in compliance with the duty of disclosure under 37 CFR § 1.56. The Examiner is requested to make this information of record in the application.


This Information Disclosure Statement is not to be construed as a representation that a full search for relevant information has been made, that all relevant information has been found, or that the information provided with this Statement is considered to be material to patentability of the claimed invention as defined under 37 CFR § 1.56(b).

PATENT  
USSN 09/593,316  
Docket 730/002

This Information Disclosure Statement is being filed after the first Office Action on the merits, pursuant to 37 CFR § 1.197(c)(2). Authorization to charge Deposit Account 07/1139 with the fee therefor under 37 CFR § 1.117(p) is provided in the accompanying fee calculation sheet.

Should any other fees be required for further consideration of the application, the Commissioner is hereby authorized to charge such fees (or credit any overpayment) to the Deposit Account.

Respectfully submitted,



J. Michael Schiff  
Registration No. 40,253

GERON CORPORATION  
230 Constitution Drive  
Menlo Park, CA 94025  
Telephone: (650) 473-7715  
Fax: (650) 473-8654

August 13<sup>th</sup>, 2004

Form 1449 (modified)	Docket: 730/002	U.S.S.N.: 09/593,316
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Title: Animal Tissue for Xenotransplantation Inventors: John Clark, et al.	
(Use Several Sheets if Necessary)	Filing Date: June 13, 2000	Group: 1632

## U.S. PATENT DOCUMENTS

Examiner Initial	Ref.	Document No.	Filing Date	Publication Date	Class/ Subclass	Inventors	Title
none							

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Ref.	Document No.	Publication Date	Juris-diction	Title	Translation
none						

## OTHER DOCUMENTS

Examiner Initial	Ref.	Author, Title, Source, Date
	FA	Angell WW et al, The Angell-Shiley Porcine Xenograft, <i>Annals of Thoracic Surgery</i> 28(6):537 (1979)
	FB	Chen CG et al, Transgenic Expression of Human $\alpha$ 1,2-Fucosyltransferase (H-Transferase) Prolongs Mouse Heart Survival in an Ex Vivo Model of Xenograft Rejection, <i>Transplantation</i> 65(6):832 (1998)
	FC	Cibelli JB et al, Cloned Transgenic Calves Produced from Nonquiescent Fetal Fibroblasts, <i>Science</i> 280:1256 (1998)
	FD	Costa C et al, Expression of the Human $\alpha$ 1,2-Fucosyltransferase in Transgenic Pigs Modifies the Cell Surface Carbohydrate Phenotype and Confers Resistance to Human Serum-Mediated Cytolysis, <i>FASEB J</i> , 13:1762 (1999)
	FE	Costa C et al, Delayed Rejection of Porcine Cartilage in Averted by Transgenic Expression of $\alpha$ 1,2-Fucosyltransferase, <i>FASEB J</i> 17:109 (2003)
	FF	Denning C et al, Deletion of the $\alpha$ (1,3)Galactosyl Transferase (GGTA1) Gene and the Prion Protein (PrP) Gene in Sheep, <i>Nature Biotechnology</i> 19:559 (2001)
	FG	Dor F et al, $\alpha$ 1,3-Galactosyltransferase Gene-Knockout Miniature Swine Produce Natural Cytotoxic Anti-Gal Antibodies, <i>Transplantation</i> 78(1):15 (2004)
	FH	Kolber-Simonds D et al, Production of $\alpha$ -1,3-Galactosyltransferase Null Pigs by Means of Nuclear Transfer with Fibroblasts Bearing Loss of Heterozygosity Mutations, <i>PNAS</i> 101(19):7335 (2004)
	FI	Kuroiwa Y et al, Sequential Targeting of the Genes Encoding Immunoglobulin- $\mu$ and Prion Protein in Cattle, <i>Nature Genetics</i> 36(7):775 (2004)
	FJ	Ramsoondar JJ et al, Production of $\alpha$ -1,3-Galactosyltransferase-Knockout Cloned Pigs Expressing Human $\alpha$ 1,2-Fucosyltransferase, <i>Biology of Reproduction</i> 69:437 (2003)
	FK	Rhind SM et al, Cloned Lambs - Lessons from Pathology, <i>Nature Biotechnology</i> 21(7):744 (2003)
	FL	Schnieke AE et al, Human Factor IX Transgenic Sheep Produced by Transfer of Nuclei from Transfected Fetal Fibroblasts, <i>Science</i> 278:2130 (1997)
	FM	Sendai Y et al, Heterozygous Disruption of the $\alpha$ 1,3-Galactosyltransferase Gene in Cattle, <i>Transplantation</i> 76(8):900 (2003)
	FN	Stinson EB et al, Long-Term Experience with Porcine Aortic Valve Xenografts, <i>J Thoracic Cardiovascular Surgery</i> 73(1):54 (1977)

Examiner	Date Considered

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
PTO-1449 — Page 1



**GERON CORPORATION**

230 Constitution Drive  
Menlo Park, CA 94025  
Telephone: 650 473-7700  
Facsimile: 650 473-7750

*Facsimile Transmittal Sheet*

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND/OR EXEMPT FROM DISCLOSURE BY APPLICABLE LAW OR COURT ORDER. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT, OR THE EMPLOYEE OR AGENT RESPONSIBLE FOR DELIVERING THE MESSAGE TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION, OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE AND RETURN THE ORIGINAL MESSAGE TO US AT THE ABOVE ADDRESS VIA THE U.S. POSTAL SERVICE. THANK YOU.

**LAST PAGE**